CLSA was greatly honored to welcome Dr. Robert Califf as the keynote speaker at our recent Evening with Thought Leaders in Los Angeles. Dr. Califf has had an extraordinarily impressive career as a cardiologist, Commissioner of the Food & Drug Administration (FDA), and now as a researcher with Duke University and advisor at Verily, an Alphabet company.
After 10 years of developing leads for clients at BioBlocks, we have created the Leap-to-Lead™ platform to offer improved Lead Discovery outcomes.
September 27 :: Capturing the Data: Improving Patient Outcomes 3:00-5:00pm :: Register Here Could the advancement of new technologies leveraging data and analytics hold the key to transforming healthcare into a more patient centric and cost efficient model? Startups are innovating in areas such as data aggregation, risk stratification, outcomes reporting and even staffing standardization … Continue reading Fall 2017 JLABS San Diego Events
On September 11, 2017, the California Life Sciences Institute (CLSI) and SENS Research Foundation (SRF) held the first “Rejuvenation Biotechnology Showcase” at the UCSF Mission Bay Conference Center with over 100 persons in attendance. The evening included a snapshot of technologies at SRF as well as presentations from four FAST graduate companies whose technologies hold … Continue reading CLSI and SENS Research Foundation Launch Rejuvenation Biology Collaboration
September 2017 Read the latest of CARB-X: CARB-X publishes first annual report. Highlighting its pipeline of 18 promising research projects with 8 new classes of antibiotics to treat the most urgent drug-resistant gram-negative bacteria. Read More CARB-XED, GARDP, ASM, and ESCMID hosted Antibiotic Bootcamps at ASM-ESCMID conference on antibiotic R&D Read More CARB-X-funded Proteus IRC’s … Continue reading CARB-X Updates
September 2017 Read the latest in FAST and Fellows news: GigaGen (FAST Spring 2015) studies published in peer-reviewed journal mAbs, on validating its novel monoclonal antibody discovery approach in mouse and human antibody repertoires Read More Former CLSA Fellow Alzeca, which is developing an imaging agent to help doctors detect Alzheimer’s disease at its earliest … Continue reading FAST & Fellows Round Up
On Sept. 11, Senate Bill 790 (McGuire) was placed on the inactive file, meaning that, while the bill is dead for this year, it will be eligible to be heard again once the legislature reconvenes in early January 2018.
Despite the best efforts of CLSA and its partner trade associations, Senate Bill 17 (Hernandez) has reached the Governor’s desk. Gov. Brown has until Oct. 13 to sign the bill for it to become law. If it’s signed, the advance notice requirements, as discussed below, would become effective on Jan. 1, 2018.
This September, CLSA participated in the 4th Annual Rally for Medical Research Hill Day to support funding for the NIH, and to continue efforts to make funding biomedical research a national priority.
On Sept. 12, the Sonoma Board of Supervisors held a new hearing on take back ordinance options for the County. At the Board’s last hearing on the subject in October of 2016, it had directed staff to begin drafting an ordinance for drug take back while also researching the potential need and possibility of including the disposal of sharps into the legislation.